Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|December 15, 2020
U-Turn or Norm? #NoGoingBack and Decentralized Trials in a post-COVID-19 World
Author(s)Oracle Health Services
*** Tuesday, December 15, 2020, at 1pm EST| 12pm CST| 10am PST *** COVID-19 has had a profound impact on clinical trials, patient recruitment and retention efforts, and accelerated the digital transformation roadmaps at sponsors and CROs. As an industry, we learned bold new ways to conduct trails. Virtual visits and remote patient monitoring have provided new options for data collection, quickly becoming the norm in the current environment recommending social distancing. But will the industry continue to embrace these changes in a post-COVID-19 world? *** On demand available after final airing until Dec. 15, 2021 ***
Register free:
Event Overview:
The effect of the pandemic on clinical trials has been profound. We have seen leaders in the pharmaceutical industry deciding with speed over precision, adapting boldly, reliably delivering and engaging for impact, to support the management of this crisis.
COVID-19 has resulted in the compression of often decades-long digital transformation roadmaps, as well as, the adoption of new innovation strategies, such as decentralized clinical trials, to respond to the realities of shelter-in-place directives.
Stakeholders have been very vocal – there is no turning back – cumulating in the
But what is the anticipated impact of decentralized clinical trials on sponsors, CROs, investigative sites, and patients? Is the industry as a whole ready to make a switch to a more patient centric approach to running clinical trials? Or more importantly, will the industry embrace this change or revert back to its old ways post-COVID-19?
Key Learning Objectives:
In this webcast we will explore:
- Impact of COVID-19 on the adoption of decentralized clinical trials
- Perceived benefits of decentralized clinical trials from a sponsor, CRO and site perspective
- Expectation of when decentralized clinical trials will be available at scale coupled with the es-timated costs relative to traditional studies
- Challenges to the implementation of decentralized clinical trials and misalignment amongst stakeholders
Speakers: Craig Lipset, Former Head of Innovation, Pfizer; Advisor and Founder, Clinical Innovation Partners
Casey Orvin, Senior VP of Pharmaceutical Relationships, Study KIK; Honorary President, SCRS
Joan Chambers, Senior Director, Marketing & Outreach Center for Information and Study on Clinical Research Participation (CISCRP)
Katherine Vandebelt, Vice President of Global Innovation, Oracle Health Sciences
Time and Date: Tuesday, December 15, 2020, at 1pm EST| 12pm CST| 10am PST
On demand available after final airing until Dec. 15, 2021
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5